At Expopharm 2025, Europe’s largest trade fair for the pharmacy market – taking place from September 16th to 18th in Düsseldorf, Four 20 Pharma (Four 20) will showcase, for the first time, the Curaleaf Que Medical Inhalation Device (QMID).
Torsten Greif and Thomas Schatton, CEO at Four 20 Pharma spoke about the QMID, and its application in the industry, “The QMID makes it possible to reliably and precisely inhale liquid cannabis. We are proud to be the exclusive distributor of this certified device in Germany.”
What is the QMID?
Curaleaf’s QMID is the first EU CE-certified liquid inhaler for cannabis-based medicines, EU Class IIa device (according to the EU Medical Device Regulation EU / 2017/745).
With each inhalation, it delivers a precise, standardised and timed dose, ensuring consistent medication intake. This dosage can be accurately quantified, enabling physicians to tailor and prescribe the medication individually for each patient.
Curaleaf’s QMID, designed in partnership with Jupiter Research LLC, a subsidiary of TILT Holdings, is a rechargeable device with a USB-C cable and a lifespan of six months after first use.
All information about the new QMID will be available exclusively at the Four 20 Pharma booth at expopharm 2025, and you can read more here: https://www.mynewsdesk.com/de/420pharma/pressreleases/neuheit-auf-der-expopharm-2025-four-20-pharma-praesentiert-exklusiv-in-deutschland-den-que-medical-inhalation-device-von-curaleaf-3402816
